

## EXTENDED REPORT

# A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs

L Klareskog, M Gaubitz, V Rodriguez-Valverde, M Malaise, M Dougados, J Wajdula, for The Etanercept Study 301 Investigators



*Ann Rheum Dis* 2006;65:1578–1584. doi: 10.1136/ard.2005.038349

See end of article for authors' affiliations

Correspondence to: L Klareskog, Rheumatology Unit, Department of Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm 17176, Sweden; Lars.Klareskog@meds.ki.se

Accepted 18 February 2006  
Published Online First 15 March 2006

**Objective:** To evaluate the long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. **Methods:** 549 patients entered this 5-year, open-label extension study and received etanercept 25 mg twice weekly. All patients showed inadequate responses to disease-modifying antirheumatic drugs before entry into the double-blind studies. Safety assessments were carried out at regular intervals. Primary efficacy end points were the numbers of painful and swollen joints; secondary variables included American College of Rheumatology (ACR) response rate, Disease Activity Score and acute-phase reactants. Efficacy was analysed using the last-observation-carried-forward approach.

**Results:** Of the 549 patients enrolled in the open-label trial, 467 (85%), 414 (75%) and 371 (68%) completed 1, 2 and 3 years, respectively; 363 (66%) remained in the study at the time of this analysis. A total exposure of 1498 patient-years, including the double-blind study, was accrued. In the open-label trial, withdrawals for efficacy-related and safety-related reasons were 11% and 13%, respectively. Frequent adverse events included upper respiratory infections, flu syndrome, rash and injection-site reactions. Rates of serious infections and malignancies remained unchanged over the course of the study; there were no reports of patients with central demyelinating disease or serious blood dyscrasias. After 3 years, ACR20, ACR50 and ACR70 response rates were 78%, 51% and 27%, respectively. The Disease Activity Score score was reduced to 3.0 at 3 months and 2.6 at 3 years from 5.1. A sustained improvement was found in Health Assessment Questionnaire scores throughout the 3-year time period.

**Conclusion:** After 3 years of treatment, etanercept showed sustained efficacy and a favourable safety profile.

The introduction of biological antirheumatic treatments, such as etanercept, in the late 1990s, represents a qualitative advance in the practice of rheumatology. In several well-controlled studies, etanercept versus placebo or methotrexate markedly reduced disease activity and rate of progression of joint damage, with limited toxicity.<sup>1–6</sup> These studies, of 24 months duration, contributed to the establishment of the efficacy and safety profile of etanercept. To more fully assess the long-term effects of treatment, studies of longer etanercept treatment in patients with rheumatoid arthritis are necessary.

Theoretical considerations in the long-term use of etanercept include immunosuppression and its effect on the development of infections and malignant tumours. To deal with these concerns, long-term data are being accumulated in this open-label extension study, which was conducted at 58 sites in 12 European countries. Incidence rates for malignancy and infection may be compared with the background statistics available from large databases.

A summary of results based on 3-year data in this ongoing study is presented in this report.

## PATIENTS AND METHODS

### Study design and patients


This is an ongoing, open-label, multicentre study on the long-term effects of etanercept in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug (DMARD) treatment. The study started in 1998, after

completion of two randomised, double-blind, placebo-controlled studies, in which patients received either placebo or etanercept for up to 6 months (fig 1). In the open-label study, which is expected to continue for up to 5 years, all patients receive etanercept 25 mg twice weekly. The ethics committee of each participating centre approved the study protocol and the consent form. Before entering the open-label study, each patient gave written informed consent.

To be included in the double-blind trials, patients had to have failed at least one DMARD, have functional class I, II or III of the American Rheumatism Association criteria for rheumatoid arthritis, and meet the 1987 American College of Rheumatology (ACR) criteria for rheumatoid arthritis. Active rheumatoid arthritis is defined by the presence of  $\geq 6$  swollen joints,  $\geq 12$  tender joints and one of the following criteria: Westergren erythrocyte sedimentation rate (ESR) of  $\geq 28$  mm/h, serum C reactive protein (CRP) concentration of  $> 20$  mg/l, or morning stiffness for  $\geq 45$  min. Onset of rheumatoid arthritis had to occur after age 16 years, and disease duration  $\leq 15$  years.

Exclusion criteria for the double-blind studies included relevant concurrent medical disease, including cancer,

**Abbreviations:** ACR, American College of Rheumatology; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; LOCF, last observation carried forward; NCI, National Cancer Institute; SAE, serious adverse event; SEER, Surveillance, Epidemiology, and End Results; TEAE, treatment-emergent adverse event; TNF, tumour necrosis factor



**Figure 1** Flow chart of patients from the double-blind studies to the long-term open-label study. BIW, twice weekly; ETN, etanercept; QW, once weekly.

uncompensated congestive heart failure, active infection, and noticeable laboratory abnormalities. Other exclusion criteria included use of any investigational drug  $\leq 3$  months before screening for the double-blind studies, use of immunosuppressive agents, or previous administration of an anti-tumour necrosis factor (TNF) agent other than etanercept. Women with childbearing potential were asked to use contraception during the study. The numbers of patients and etanercept treatment regimens for the two double-blind studies are shown in fig 1.

### Drugs

During the open-label study, etanercept 25 mg was self-administered subcutaneously twice weekly. Permitted concomitant drugs include non-steroidal anti-inflammatory drugs, corticosteroids ( $\leq 10$  mg/day prednisolone or equivalent), analgesics, and physical, herbal and homeopathic treatments. No intra-articular corticosteroid injection was permitted for the first 3 months. Thereafter, the total allowed dose of corticosteroid injection did not exceed the equivalent dose of 40 mg prednisone in any 3-month period. Treatment with a DMARD or cytotoxic drug was prohibited.

### Clinical evaluation

After completion of the double-blind studies, patients entering the open-label study were evaluated clinically and variables including swollen and tender joint counts (66/68 counts),<sup>7</sup> pain Visual Analogue Scale (VAS), Health Assessment Questionnaire (HAQ), and patient and physician global assessments of disease activity were considered, at

baseline, week 2, week 4 and monthly thereafter. ESR and CRP were assessed at baseline, week 2, week 4, and at 12-week intervals, thereafter. Patients were evaluated by the same assessor whenever feasible throughout the study.

Safety evaluations, including physical examination, adverse experiences, vital signs, routine blood biochemistry and haematology analysis, were carried out at week 2, week 4, and monthly thereafter, for the first year of the open-label study and every 3 months thereafter, for the remainder of the study.

An event was considered to be a treatment-emergent adverse event (TEAE) if it occurred during the study or if the severity or frequency of a pre-existing event increased during the study. A serious adverse event (SAE) was any event that resulted in death; was life threatening, required hospitalisation, or medical or surgical intervention; resulted in persistent or marked disability, cancer; or was a congenital defect. Infections were serious if they met the definition of an SAE.

The incidence of malignancies was compared with the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER)<sup>8</sup> database. The age-specific and sex-specific incidence rates for cancer from the SEER database were applied to the exposure in this study.

### Statistical analyses

In this open-label study, the emphasis was on descriptive statistics and the primary objectives were safety parameters. The baseline used for safety parameters was the start of the open-label study. Assessment of clinical efficacy of etanercept was a secondary objective. The main efficacy end points were numbers of painful and swollen joints. Efficacy parameters analysed with the last observation carried forward (LOCF) were based on patients who received at least one dose of etanercept, the intent-to-treat population. Baseline values for efficacy parameters were assessed before the start of etanercept treatment—that is, before the double-blind trials for patients who received etanercept—and before the open-label study for patients who received placebo during the double-blind trials.

The power of this study was estimated as the probability of encountering  $\geq 1$  adverse event given a true underlying incidence. With 549 patients, there is a 50% chance that an adverse event with a 0.13% incidence would be observed, an

**Table 1** Patient baseline characteristics before treatment

Total enrolled	549
Mean age (years)	53
Women (%)	79
Patients on prior NSAIDs (%)	87
Patients on prior corticosteroids (%)	84
Mean no of prior DMARDs	3.3
No of tender joints	31.0
No of swollen joints	22.4
RF+ (%)	86.4
Mean RA duration (years)	7.4

DMARDs, disease-modifying antirheumatic drugs; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor.

**Table 2** Percentage (number) of patients who withdrew (primary reasons)

Reason for discontinuation	Year 1	Year 2	Year 3	>3 years*	Total
Any reason	15 (82)	10 (53)	8 (43)	1 (8)	34 (186)
Adverse events	5 (30)	4 (20)	3 (19)	<1 (4)	13 (73)
Unsatisfactory response	5 (29)	2 (11)	3 (16)	<1 (2)	11 (58)
Other non-medical event	1 (7)	3 (14)	<1 (1)	<1 (1)	4 (23)
Patient request	1 (6)	1 (6)	<1 (3)	<1 (1)	3 (16)
Protocol violation	2 (9)	<1 (2)	<1 (2)	0 (0)	2 (13)
Failed to return	<1 (1)	0 (0)	<1 (2)	0 (0)	<1 (3)

\*Till the cut-off date (31 August 2001).

80% chance for an adverse event with a 0.30% incidence and a 90% chance for one with a 0.44% incidence.

## RESULTS

### Patient characteristics

Table 1 summarises the characteristics of the patients before treatment.

### Exposure

In total 549 adult patients with rheumatoid arthritis received etanercept 25 mg twice weekly. The minimum, maximum and median exposure was 8 days, 3.92 and 3.34 years, respectively. A total of 1396 patient-years have been accrued in this open-label study.

### Safety and tolerability

Throughout the study, the two most common reasons for discontinuation from etanercept were adverse event and unsatisfactory response (table 2). As on the cut-off date (31 August 2001), 363 patients continue to receive etanercept in this ongoing trial.

We found no predominant adverse events leading to discontinuation. The most common adverse events leading to discontinuation were pruritus (n = 4), and abscess, injection-site reaction, rash, sepsis, pneumonia, myocardial infarction and pyogenic arthritis (n = 3 for each). The most frequently reported TEAEs included upper respiratory infection, accidental injury, injection-site reaction and flu syndrome (table 3). We found no cases of demyelinating disease of the central nervous system.

NCI grades (3 and 4) were used to identify patients with test results of potential clinical importance. The most common grade 3 and 4 laboratory abnormalities were increased alanine

aminotransferase (n = 12), low lymphocytes (n = 10) and low albumin (n = 9). One patient had low platelet values (lowest value =  $35 \times 10^9/l$ ) for three consecutive visits, but continued in the study. Another patient had increased alanine aminotransferase for two consecutive visits. This patient was withdrawn from the study because of a protocol violation, non-compliance with study drugs. The remaining patients had transient grade 3 or 4 laboratory abnormalities. No persistent clinically relevant laboratory abnormalities were found. Five patients (0.9%) discontinued because of a laboratory abnormality that was not classified as grade 3 or 4.

### Serious infections

Rates of serious infections requiring hospitalisation or requiring parenteral antibiotics remained unchanged over the extended course of the study (table 4). The most frequently reported serious infections were pneumonia, upper respiratory infection, abscess, bronchitis, gastroenteritis, septic arthritis, sepsis, peritonitis and wound infection.

Of the 10 patients who died during or after discontinuation from the study, 7 had infection as a contributory factor to their deaths (table 5).

Of the 14 patients with a history of tuberculosis, none experienced tuberculosis reactivation. One case of suspected tuberculosis was reported in a patient in Spain with a history of occupational pneumoconiosis (Caplan's syndrome); this patient had a positive tuberculin test without evidence of mycobacterium.

### Malignancies

Among the malignancies reported, no clustering around any specific type of cancer was observed. The most commonly reported tumour types were breast (n = 3) and lung (n = 2) carcinomas. We found one report of lymphoma in a 59-year-old patient with disease duration of 4.5 years and 323 days of etanercept treatment. The patient was diagnosed with Hodgkin's lymphoma 8 months after discontinuing etanercept treatment. Because malignancies develop over a long time, the exposure data captured in table 6 included those of the patients treated with etanercept in the double-blind studies. The rates per patient-year remained stable throughout the study. Compared with the SEER database, the number of cases observed is lower (n = 11) than the number of cases expected (n = 13), on the basis of etanercept

**Table 3** Most frequently reported treatment-emergent adverse events

Adverse event	% of patients	Events per patient-year*
Upper respiratory infection	38	0.34
Accidental injury	26	0.14
Injection-site reaction	26	0.43
Flu syndrome	21	0.11
Infection	19	0.10
Rash	17	0.09
Abdominal pain	16	0.09
Pharyngitis	15	0.08
Back pain	15	0.08
Bronchitis	15	0.10
Headache	14	0.10
Rhinitis	14	0.08
Diarrhoea	13	0.07
Cough increased	13	0.07
Arthralgia	11	0.06
Hypertension	11	0.05
Urinary tract infection	11	0.07
Injection-site haemorrhages	10	0.35

\*Open-label exposure.

**Table 4** Serious infections

Parameter	Years on etanercept			Total (n = 549)
	0-1 (n = 549)	1-2 (n = 468)	2->3 (n = 421)	
Patient-years	501	446	448	1396
No of events	37	26	26	89
Infections per 100 patient-years	7.4	5.8	5.8	6.4

**Table 5** Deaths: days on treatment and associated conditions

Relative days on open-label treatment	Clinical profile at the time of death
32	Cardiorespiratory failure after recovery from peritonitis and sepsis*
39	Disseminated carcinoma, sepsis*
53	Agranulocytosis (due to thiamazole), sepsis with multiorgan failure*
221	Renal failure, cholecystitis, cholelithiasis*
716	Alcoholic hepatitis, pneumonia*
950	Sudden death, pneumonia*
1007	Car accident
1131	Acute heart failure
1149	Pulmonary embolism
1154	Cardiac arrest (chronic cardiomyopathy, possibly pulmonary embolism, bacteraemia without clinical symptoms of sepsis)*

\*Associated with infection.

exposure. Because the SEER database<sup>8</sup> does not include non-melanoma skin cancers, the two reports of basocellular skin cancers were excluded from the comparison.

**Efficacy**

The percentage of patients meeting ACR20 criteria remained relatively stable throughout the trial, and was at 77.8% at month 36. Although not significant, the percentage of patients meeting ACR50 increased with time on etanercept, from 39.5% at month 3 to 50.6% at month 36. Similarly, the ACR70 rate was 18.6% at month 3 and 27.0% at month 36 (fig 2). The mean baseline Disease Activity Score score of 5.1 decreased to 3.0 at month 3 and continued to decrease thereafter (fig 3).

After 3 months of treatment, a substantial reduction in the numbers of painful and swollen joints was achieved, 11.6 (63%) and 8.0 (65%), respectively. At 3 years, the numbers were reduced to 8.9 (71%) and 6.2 (72%), respectively (fig 4).


The mean baseline CRP and ESR concentrations were 43.4 mg/l and 44.3 mm/h, respectively. At month 3, they decreased to 17.5 mg/l and 26.2 mm/h, respectively, and at month 36, to 12.1 mg/l and 24.8 mm/h, respectively (fig 5).

The baseline median HAQ score of 1.8 decreased to 1.1 at 3 months and was maintained thereafter; at month 36, the median HAQ score was 1.1, representing a 39% improvement from baseline (fig 3). The mean physician and patient global assessments of 6.6 and 6.7, respectively, at baseline decreased to 2.9 and 3.4, respectively, at month 3, with a small additional improvement by month 36. Patient pain scores improved from baseline by 50% at month 3 and by 49.2% at month 36.


**Table 6** Incidence of malignancies

Parameter	Years on etanercept			Total (n = 549)
	0-1 (n = 549)	1-2 (n = 479)	2->3 (n = 430)	
Patient-years*	516	455	527	1498
No of events	3	5	3	11
Malignancies per 100 patient-years	0.6	1.1	0.6	0.7


\*Includes double-blind and open-label exposure data for those patients who entered the extension trial. Expected cases: 13 based on the National Cancer Institute Surveillance, Epidemiology, and End Results database.




**Figure 2** Percentage of patients with American College of Rheumatology (ACR)20, ACR50 and ACR70 response rates by study month. \*Baseline of previous double-blind studies.



**Figure 3** Mean Disease Activity Score (DAS) and median Health Assessment Questionnaire (HAQ) scores by study month. \*Baseline of previous double-blind studies.



**Figure 4** Percentage change from baseline in the numbers of painful and swollen joints by study month. \*Baseline of previous double-blind studies.



**Figure 5** Median C reactive protein (CRP) and median erythrocyte sedimentation rate (ESR) by study month. \*Baseline of previous double-blind studies. ULN, upper limit of normal.

## DISCUSSION

This multicentre, open-label study confirmed that etanercept monotherapy provides a sustained favourable efficacy and safety profile. Retention rates were similar<sup>9</sup> or higher<sup>10–13</sup> than those seen in long-term studies of etanercept and other rheumatoid arthritis treatments. Over the 3 years, patients showed no increase in TEAEs or SAEs, and there were no reports of tuberculosis recurrence. The incidence of malignancy was similar to that of the general population.

One limitation of this multicentre study is its open-label design—that is, subjects and investigators are not blinded—which could introduce bias. However, it would be inappropriate to consider a placebo-controlled study to evaluate the long-term safety and efficacy of a treatment for rheumatoid arthritis. Open-label studies with careful monitoring and with the option of comparing results between different time periods thus represent one important possibility of obtaining results that are of relevance to the clinical practice.

In our study, 66% of patients were receiving etanercept after 3 years. This retention rate is similar to the 63% observed in a similar long-term study of North American patients with rheumatoid arthritis.<sup>9</sup> Adherence rates for DMARD treatments are available only in published long-term observational studies. In a 14-year prospective observational study of 671 patients with rheumatoid arthritis attending an outpatient clinic,<sup>12</sup> the approximate percentage of patients remaining on treatment was 55% for methotrexate, 40% for hydroxychloroquine, 39% for penicillamine, 39% for gold injection and 35% for auranofin at 3 years.<sup>12</sup> Regardless of study design, patients receiving inadequate or unsatisfactory treatment would have a similar desire to discontinue. Therefore, despite the differences in the studies discussed here, the longer retention rates observed in our open-label trial suggest that etanercept may be well tolerated or more efficacious than most DMARDs.

In previously reported double-blind placebo-controlled studies, the rate of infections with etanercept was not markedly different from that with placebo.<sup>2–6</sup> Adverse events, including incidence of infection reported in this open-label study, were comparable with those in the placebo arm of the preceding double-blind study<sup>14</sup> even after 3 years of continuous drug exposure. This safety profile is reassuring, because it has been assumed that long-term inhibition of TNF would increase the risk of infection.<sup>15–17</sup> However, the data need to be interpreted with some caution, because this long-term extension study included patients from two randomised double-blind trials with strict inclusion and exclusion criteria, which may differ from many clinical practice populations in terms of comorbidities and drugs.

The association between tuberculosis and other intracellular infections with various anti-TNF treatments is another potential area of concern.<sup>18</sup> Although patients with a history of tuberculosis were not excluded from this study, none of the 14 patients with a documented history of tuberculosis had any recurrence or exacerbation of infection during the trial. Tuberculosis was suspected in one patient from Spain who received etanercept treatment for more than 3 years.

Another long-term potential consequence of TNF inhibition is an increased risk of malignancy secondary to the possible role of TNF in tumorigenesis.<sup>19</sup> In this long-term study, the number of malignancies per patient-year, including skin cancers, was reported to be 0.009. Although study designs differed, rates of malignancies were similar to those obtained from a long-term follow-up of 521 patients with rheumatoid arthritis at the Mayo Clinic (Rochester, Minnesota, USA) (0.018)<sup>20</sup> and a controlled retrospective cohort study of 623 patients with rheumatoid arthritis in The Netherlands (0.012).<sup>21</sup> Furthermore, in a register-based study in Sweden on patients subject to treatment with TNF-blocking agents in clinical practice, the standardised incidence ratio (observed/expected numbers of cancers) was 0.9 (95% CI 0.7 to 1.2).<sup>22</sup>

The number of observed cases ( $n = 11$ ) of malignancy is fewer than that expected ( $n = 13$ ) based on the age-matched and sex-matched general population from the NCI SEER<sup>8</sup> database, a database of cancers (not including non-melanoma skin cancers) that have been reported in North America. The SEER database was used to provide an approximation of the rate of malignancies in the general population worldwide. Although not specific for Europe, this database provides approximate rates of malignancy in the general population. The incidence of malignancy was relatively constant in each of the 3 years of treatment, with no unusual clustering of any particular cancer. The one reported case of lymphoma had a questionable relationship to etanercept: the patient had received almost 11 months of etanercept and developed Hodgkin's lymphoma 8 months after discontinuation. Overall, it seems that the malignancies among this patient population are representative of a chronic rheumatoid arthritis population.

Although the designs of the studies listed in table 7 were different, mortality was consistent. The rate of seven infection-related deaths per 1498 patient-years is comparable with infection-related mortality in patients with rheumatoid arthritis from published sources and a large US registry (table 7).<sup>21, 23–25</sup>

The extent to which the infections were associated with the fatal outcome is not clear because most patients had other comorbid conditions. Studies have shown that patients with rheumatoid arthritis have higher mortality than the general population.<sup>26</sup> Gabriel *et al*<sup>27</sup> reported that the risk of mortality is approximately 38% greater in patients with rheumatoid arthritis than in the general population. The risk was dramatically higher at 55% in women with rheumatoid arthritis than in the general population.<sup>27</sup> Wolfe *et al*<sup>25</sup> reported 4–13 times higher infection-related mortality for patients with rheumatoid arthritis than for the general population. For pneumonia, the mortality was 3–6 times higher for patients with rheumatoid arthritis.<sup>25</sup>

Another concern in connection with anti-TNF treatment is central demyelination. Although reports have described how TNF inhibitors could worsen demyelinating conditions,<sup>28</sup> there were no reports of demyelinating disease of the central nervous system (eg, multiple sclerosis or optic neuritis) in this long-term study. However, more long-term etanercept exposure is required before a full assessment can be made.

The overall treatment response from any of the efficacy variables, including Disease Activity Score, was attained early

**Table 7** Infection-related mortality in patients with rheumatoid arthritis

Source	Year of publication	No of patients	Estimated exposure (patient-years)	Estimated mortality per 100 patient-years
This report (Europe)	2006	549	1498*	0.47
Duthie <i>et al</i> (UK)	1964	307	2240	0.49
Prior <i>et al</i> (UK)	1984	448	5018	0.64
Wolfe <i>et al</i> (US) <sup>25</sup>	1994	3501	29 200	0.62
van den Borne <i>et al</i> (The Netherlands) <sup>21</sup>	1998	415	2280	0.39

\*Includes both double-blind and open-label etanercept exposure.

and maintained throughout the 3-year period. These results are in agreement with a North American long-term open-label study, which showed that the efficacy of etanercept is sustained and well tolerated.<sup>10</sup> Both studies enrolled similar DMARD-refractory patients, who were not allowed to receive other antirheumatic drugs during the trial. Consequently, the results achieved in this study do not reflect the potential additive effects of combination therapy.

Improvement in the signs and symptoms of rheumatoid arthritis occurred early and were sustained over the 3-year period. An ACR20 response rate  $\geq 75\%$  was achieved and maintained from 3 to 36 months. This was similar to US long-term data, in which 73% and 76% of patients treated with etanercept achieved ACR20 response rate at 30 months<sup>10</sup> and  $\sim 48$  months.<sup>29</sup> ACR50 and ACR70 response rates of 39.5% and 18.6%, respectively, seen 3 months after the start of the open-label extension, tended to increase over the 36 months. The ACR50 results are consistent with previously reported response rates in a double-blind, controlled trial.<sup>5</sup> ACR70 response rate at 3 months is higher than that observed after 3 months in other double-blind trials. One possible explanation is that patients entering the open-label trial were not etanercept-naïve; they had received 1–6 months of treatment during the double-blind trial. Another potential factor is the open-label design; patients have a more positive response when they know they are receiving active drugs.

One of the challenges encountered when designing a long-term study is accounting for missing data points or discontinuations before the end of the study. We chose to use the LOCF to capture the early responders who discontinued for reasons other than lack of efficacy. An analysis including only the patients completing 3 years could introduce bias because these patients were more likely to be treatment responders. In our study, ACR response rates derived using a completers analysis were higher than the rates derived using an LOCF analysis; percentages of ACR20, ACR50 and ACR70 responders were 85.9%, 59.1% and 31.8%, respectively, at 3 years.

Similar sustained responses were seen with the quality-of-life measures on disability functions; the mean percentage change from baseline for the HAQ score was improved by 40.7% at 3 months and maintained for 3 years. These results are clinically relevant because patients with rheumatoid arthritis experience varying degrees of physical impairment, fatigue, reactive depression and weight loss.<sup>30</sup>

In conclusion, etanercept shows a favourable safety and efficacy profile for  $>3$  years of treatment, and continues to provide significant clinical benefit in the patient population evaluated in this study. Etanercept represents a long-term treatment option in clinical practice.

## ACKNOWLEDGEMENTS

This study was supported by Wyeth Research, Collegeville. We thank Pamela Yeh, PharmD, Donna Simcoe, MS, and Ruth Pereira, PhD, for assistance with the preparation of the manuscript.

## Authors' affiliations

**L Klareskog**, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

**M Gaubitz**, Kooperatives Rheumazentrum Munster, Munster, Germany

**V Rodriguez-Valverde**, Hospital Universitario Marqués de Valdecilla, Santander, Spain

**M Malaise**, CHU Sart Tilman, Liege, Belgium

**M Dougados**, Hospital Cochin, Paris, France

**J Wajdula**, Wyeth Research, Collegeville, Pennsylvania, USA

Competing interests: LK has received research grants and has been consultant and speaker on symposia arranged by Wyeth, Schering Plough, Abbott, Bristol Myers Squibb and Amgen. VR-V has participated in clinical trials sponsored by Abbott, Schering Plough, Wyeth, and has given lectures paid by Schering Plough and Wyeth. MD has been paid by Wyeth for running educational programmes, and has received grants from Wyeth for conducting research. MG is a paid participating investigator and has given lectures for Wyeth Research. JW is an employee of Wyeth Research.

Etanercept Study 301 Investigators: A Alonso Ruiz, Baracaldo, Spain; D Andersone, Pilsone, Latvia; JM Aranburu, Bilbao, Spain; PA Bacon, Birmingham, UK; P Benito Ruiz, Barcelona, Spain; HJ Bergerhausen, Recklinghausen, Germany; P Bertin, Limoges, France; U Botzenhardt, Bremen, Germany; H Bird, West Yorkshire, UK; J Bratt, Huddinge, Sweden; L Carreno, Madrid, Spain; J Castenhag, Karlstad, Sweden; G Chales, Rennes, France; R Dahl, Uppsala, Sweden; B Danneskiold-Samsøe, Frederiksberg, Denmark; M Dougados, Paris, France; G Ferraccioli, Udine, Italy; M Figueroa, San Sebastian, Spain; O Forre, Oslo, Norway; S Freiesleben Sorensen, Kobenhavn, Denmark; M Gaubitz, Munster, Germany; J Gijon, Madrid, Spain; JJ Gomez Reino, Santiago De Compostela, Spain; J Goobar, Ostersund, Sweden; N Graudal, Herlev, Denmark; H Haentzschel, Leipzig, Germany; G Hein, Jena, Germany; JR Kalden, Erlangen, Germany; JP Kaltwasser, Frankfurt, Germany; JL Kuntz, Strasbourg, France; H Lang, Plauen, Germany; I Leden, Kristianstad, Sweden; B Lindell, Kalmar, Sweden; M Malaise, Liège, Belgium; E Martin Mola, Madrid, Spain; O Meyer, Paris, France; N Misiuniene, Kaunas, Lithuania; M Mousa, Visby, Sweden; H Nielsen, Herlev, Denmark; M Nissila, Heinola, Finland; H Nusslein, Dresden, Germany; T Helve, Helsinki, Finland; O Karjalainen, Oulu, Finland; L Klareskog, Stockholm, Sweden; M Korpela, Pikonlinna, Finland; R Luukkainen, Rauma, Finland; JL Marengo, Sevilla, Spain; R Oding, Vasteras, Sweden; JL Pasquali, Strasbourg, France; E Rankin, Birmingham, UK; V Rodriguez Valverde, Santander, Spain; J Sany, Montpellier, France; L Sköldstam, Kalmar, Sweden; G Simenon, Bruxelles, Belgium; JG Tebib, Pierre Benite, France; J Tornero, Guadalajara, Spain; S Transo, Jonkoping, Sweden; M Vallgarda Ojert, Orebro, Sweden; H Warnatz, Essen, Germany; D Wendling, Besancon, France; A Wittenborg, Recklinghausen, Germany; H Zeidler, Hannover, Germany.

## REFERENCES

- 1 **Bathon JM**, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, *et al*. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [comment] [erratum appears in *N Engl J Med* 2001;344:240]. *N Engl J Med* 2000;**343**:1586–93.
- 2 **Weinblatt ME**, Kremer JM, Bankhurst AD, Bulpiitt KJ, Fleischmann RM, Fox RL, *et al*. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* 1999;**340**:253–9.
- 3 **Moreland LW**, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpiitt KJ, *et al*. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Ann Intern Med* 1999;**130**:478–86.

- 4 **Genovese MC**, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. *Arthritis Rheum* 2002;**46**:1443–50.
- 5 **Klareskog L**, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis. *Lancet* 2004;**363**:675–81.
- 6 **Moreland LW**, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [comment]. *N Engl J Med* 1997;**337**:141–7.
- 7 **Felson DT**, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum* 1993;**36**:729–40.
- 8 Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973–1999) [11 Registries, 1992–1999]. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission.
- 9 **Genovese MC**, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. *J Rheumatol* 2005;**32**:1232–42.
- 10 **Moreland LW**, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. *J Rheumatol* 2001;**28**:1238–44.
- 11 **Morand EF**, McCloud PI, Littlejohn GO. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. *Ann Rheum Dis* 1992;**51**:1318–21.
- 12 **Wolfe F**, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. *J Rheumatol* 1990;**17**:994–1002.
- 13 **Kalden JR**, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. *Arthritis Rheum* 2003;**48**:1513–20.
- 14 **Klareskog L**, Wajdula J, Pedersen R. A long-term open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis) [abstract]. *Ann Rheum Dis* 2001;**61**:FRI0050.
- 15 **Havell EA**. Evidence that tumor necrosis factor has an important role in antibacterial resistance. *J Immunol* 1989;**143**:2894–9.
- 16 **Flynn JL**, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. Tumor necrosis factor-alpha is required in the protective immune response against *Mycobacterium tuberculosis* in mice. *Immunity* 1995;**2**:561–72.
- 17 **Laichalk LL**, Kunkel SL, Strieter RM, Danforth JM, Bailie MB, Standiford TJ. Tumor necrosis factor mediates lung antibacterial host defense in murine *Klebsiella pneumoniae*. *Infect Immun* 1996;**64**:5211–18.
- 18 **Gershon S**, Wise RP, Niu M, Siegel J. Postlicensure reports of infection during use of etanercept and infliximab. *Arthritis Rheum* 2000;**43**:2857.
- 19 **Aggarwal BB**. Signalling pathways of the TNF superfamily: a double-edged sword. *Nat Rev Immunol* 2003;**3**:745–56.
- 20 **Katusic S**, Beard CM, Kurland LT, Weis JW, Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. *Am J Med* 1985;**78**:50–5.
- 21 **van den Borne BE**, Landewe RB, Houkes I, Schild F, van der Heyden PC, Hazes JM, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. *Arthritis Rheum* 1998;**41**:1930–7.
- 22 **Askling J**, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. *Ann Rheum Dis* 2005;**64**:1421–6.
- 23 **Duthie JR**, Brown PE, Truelove LH, Baragar FD, Lawrie AJ. Course and prognosis in rheumatoid arthritis: a further report. *Ann Rheum Dis* 1964;**23**:193–204.
- 24 **Prior P**, Symmons DP, Scott DL, Brown R, Hawkins CF. Cause of death in rheumatoid arthritis. *Br J Rheumatol* 1984;**23**:92–9.
- 25 **Wolfe F**, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. *Arthritis Rheum* 1994;**37**:481–94.
- 26 **Doran MF**, Gabriel SE. Infections in rheumatoid arthritis—a new phenomenon? *J Rheumatol* 2001;**28**:1942–3.
- 27 **Gabriel SE**, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? [see comments]. *J Rheumatol* 1999;**26**:2529–33.
- 28 **Mohan N**, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. *Arthritis Rheum* 2001;**44**:2862–9.
- 29 **Genovese M**, Martin R, Fleischmann R, Keystone E, Bathon J, Finck B, et al. Etanercept (Enbrel) in early erosive rheumatoid arthritis (ERA trial): observations at 3 years [abstract]. *Arthritis Rheum* 2001;**44**(Suppl):S78.
- 30 **Kosinski M**, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. *Am J Manage Care* 2002;**8**:231–40.